Gsk Share Discussion Threads

[tradermichael] 06/11/2022 12:11

GSK PLC said Thursday that it will stop patient recruitment early for two trials of gepotidacin, a treatment for urinary tract infections, following a recommendation by the Independent Data Monitoring Committee.

The pharmaceutical giant said that the decision was based on a pre-specified interim analysis of efficacy and safety data in more than 3,000 patients across the trials. However, it added that the IDMC review didn't identify any safety concerns.

The EAGLE-2 and EAGLE-3 trials met the primary efficacy endpoint, GSK said. The company also said that it plans to submit a new drug application for gepotidacin with the U.S. Food and Drug Administration in the first half of next year.

"The IDMC's recommendation to stop the EAGLE-2 and 3 trials early for efficacy provides GSK with the opportunity to engage regulatory authorities as we work together to bring a new class of antibiotics to patients with uUTIs [Uncomplicated urinary tract infections]," GSK's senior vice president for development Chris Corsico said.

[geckotheglorious] 03/11/2022 16:15

In case anyone interested...

"Efficacy and Safety of Bivalent Respiratory Syncytial Virus (RSVpreF)
Vaccine in Older Adults"

[tradermichael] 03/11/2022 12:18

Bank of England raises interest rates to 3%

[suetballs] 03/11/2022 10:12

Although "alleged" you still have to defend yourself - unfortunately.
Suet

[anhar] 03/11/2022 10:12

After the close of day 1 trading, GSK consolidated its existing shares, returning the share price to around the same as before demerger. This was to ensure comparability of the company’s earnings per share and share price with previous periods

Not really, that's just the BS they tell you. The real reason for these consolidations following demergers and cash returns is cosmetic and face-saving, ie. to avoid what they see as the shame arising from the price fall that would have to occur without the consol. There's no real need for such consols at all, but I guess they make a few bucks for the advisers.

[tradermichael] 03/11/2022 10:05

Add 'no causal link has been scientifically proven'

[alphorn] 03/11/2022 09:43

Add 'alleged'.

[lippy4] 03/11/2022 09:37

reported today in the telegraph that gsk have put aside £45 million to fight the claims being made against it for selling the cancer causing drug..

[tradermichael] 03/11/2022 09:22

After the close of day 1 trading, GSK consolidated its existing shares, returning the share price to around the same as before demerger. This was to ensure comparability of the company’s earnings per share and share price with previous periods

[zho] 03/11/2022 09:22

>>Therefore why didn't the price of new GSK go down on demerger day?>>

It did go down - that's the inverse spike you can see in the graph above in mid July.

The 5 for 4 consolidation meant that the share price post split was roughly the same as pre split, but the value of GSK now (the pharma part of the business) is only 4/5th of the value of GSK pre split (pharma + HLN).

[stewart64] 03/11/2022 09:06

I wasn't a holder of GSK on demerger day, so didn't go into the mechanics at that time. But wondered if someone can answer this query please. I understand that 5 shares in old GSK became 4 shares in new GSK. Yet Haleon is worth considerably more than one quarter of new GSK. Therefore why didn't the price of new GSK go down on demerger day? Or did the price adjustment occur later and by what factor.

As I'm assuming comparing the old and new GSK price isn't comparing like with like?

[tradermichael] 03/11/2022 07:54

Sales of 7.83 billion pounds for the third quarter, up from GBP6.63 billion the year prior, and beating a company-provided consensus of GBP7.32 billion is hardly an underperformance!

[paul planet earth] 02/11/2022 20:54

Market thinks GSK under performed and the spin off of Haleon was a complete disaster hence lack lustre share price performance!

[rikky72] 02/11/2022 18:06

Yes, a shame all the gains were lost but then the general market was down too which didn't help. Some positive signs though.

[abdullla] 02/11/2022 16:35

Nothing has changed except the share price has tanked!

[tradermichael] 02/11/2022 14:11

Nothing has changed, in particular, except this:

GSK delivers strong Q3 2022 sales of £7.8 billion +18% AER, +9% CER and Total EPS 255.9p +>100% AER, +>100% CER; Adjusted EPS of 46.9p +25% AER, +11% CER

[stewart64] 02/11/2022 10:58

Aren't we looking at a 30% potential liability on Zantac shared with other Companies amounting to 2 billion for GSK against 60 billion Market Cap?

[tradermichael] 02/11/2022 10:24

Zantac
The Zantac litigation continues in federal and state courts in the
United States. GSK's position on the scientific validity of these
cases has not changed since the last reporting period. GSK will continue
to defend all claims vigorously.

GSK has been named as a co-defendant in approximately 4,100 filed
personal injury cases in federal and state court. There are approximately
77,000 plaintiffs named in these cases. A significant majority of
these plaintiffs were named in a series of multi-plaintiff complaints
recently filed in Delaware state court and most of these plaintiffs
were previously in the Multidistrict Litigation (MDL) Census Registry
in the Southern District of Florida. They were removed because they
allege a cancer other than the 5 cancers being pursued by the MDL
plaintiffs. In the MDL, plaintiffs originally identified 10 different
types of cancers they wished to pursue. Plaintiffs subsequently dropped
5 of the 10 cancers, and they are proceeding only as to bladder,
esophageal, gastric, liver, and pancreatic, although plaintiffs in
state courts continue to pursue claims beyond the 5 designated cancers.
There are approximately 33,000 unfiled claims relating to GSK and
other co-defendants concerning the 5 designated cancers in the MDL
Census Registry. There are also over 2,000 California state court
cases subject to an agreement between GSK and the plaintiffs which
suspends the statute of limitations to allow the plaintiffs to bring
their claims at a later date. These filed and unfiled counts are
subject to change.

As planned, in September and October 2022, the MDL Court held hearings
on the admissibility of each side's general causation expert witnesses
("Daubert hearings"). Based on the 12 epidemiological studies conducted
looking at human data regarding the use of ranitidine, the scientific
consensus is that there is no consistent or reliable evidence that
ranitidine increases the risk of any type of cancer. The 12th additional
epidemiologic study (Wang et al. (2022)) was recently released. When
comparing ranitidine to an active comparator (famotidine), Wang 2022
found a statistically significant increased risk with regard to liver
cancer (Hazard Ratio 1.22, 95% Confidence Interval 1.06-1.40) and
no statistically significant increased risk for the remaining 4 cancers
pursued in the MDL. Consistency across available epidemiological
evidence, particularly where reported potential associations are
modest, is critical for drawing reliable conclusions about causation.
The parties await a decision from Judge Robin L. Rosenberg.

In the California Zantac litigation Cases JCCP 5150 (JCCP), the Court
will hold a Sargon hearing on 25 January 2023 regarding the admissibility
of expert witnesses, including general causation expert witnesses,
for the first bellwether trials. The first bellwether trial is expected
to start on 13 February 2023 in the California JCCP.

The Illinois Supreme Court recently consolidated all Illinois ranitidine
cases in Cook County for pretrial proceedings with trial dates to
be set, including the previously scheduled Madison County trial.

Given the complex ownership and marketing of Zantac prescription
and over-the-counter (OTC) medicine over many years, numerous claims
involve several defendants. As a result, some defendants have served
one another, including GSK, with notice of potential indemnification
claims about possible liabilities connected particularly with Zantac
OTC. Given the early stage of the proceedings, GSK cannot meaningfully
assess what liability, if any, it may have, nor can it meaningfully
assess the liability of other parties under relevant indemnification
provisions.

Further information regarding the litigation can be found in GSK's
11 August 2022 and 16 August 2022 statements.

[southwinds] 02/11/2022 10:19

There has been no update about the significance ongoing litigation with regard to Zantac being carcinogenic , maybe with the midday results presentation.

[tradermichael] 02/11/2022 08:44

Don't forget OLD GSK = New GSK + HLN. Then understand that for Haleon, analysts estimate an annual dividend of six pence a share in 2023 and seven pence in 2024. So longer term holders can add that to their GSK dividend income .... ;0)

[stewart64] 02/11/2022 08:40

Possibly the 13.75p dividend per share was a disappointment for some. The days of paying out all the profits have gone.

[purchaseatthetop] 02/11/2022 08:16

Very good figures.

[tuftymatt] 02/11/2022 08:10

I am happy and should have done more of what WB would have done when we were circa 1300!!

"Be greedy when others are fearful"

[tradermichael] 02/11/2022 08:10

GSK PLC on Wednesday raised its guidance for the full year and posted rising sales for the third quarter that beat expectations.

The British pharma major posted sales of 7.83 billion pounds ($8.99 billion) for the third quarter, up from GBP6.63 billion the year prior, and beating a company-provided consensus of GBP7.32 billion.